Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal structure of the omalizumab–Fab in complex with an IgE-Fc fragment. This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with both high- and low-affinity IgE receptors, and explains why omalizumab selectively binds free IgE. The structure of the complex also provides mechanistic insight into a class of disruptive IgE inhibitors that accelerate the dissociation of the high-affinity IgE receptor from IgE. We use this structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab binding. Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with omalizumab, promotes the exchange of cell-bound full-length IgE with omalizumab-resistant IgE-Fc fragments on human basophils. This combination treatment also blocks basophil activation more efficiently than either agent alone, providing a novel approach to probe regulatory mechanisms underlying IgE hypersensitivity with implications for therapeutic interventions.
Allergic diseases represent an over-reaction of the immune system to normally non-hazardous environmental substances, such as dust mites, pet dander, pollen or mold, and the incidence of allergies worldwide is rising. IgE antibodies are central to most allergic reactions, and bind to high-affinity receptors (FcεRI) on present mast cells and basophils, sensitizing these cells to respond to allergens. FcεRI is expressed as a trimer with one α-chain and two γ-chains or as a tetramer with an additional β-chain. The FcεRI α-chain (FcεRIα) binds IgE with subnanomolar affinity, and cells expressing FcεRI are preloaded with IgE and primed for activation. A second IgE receptor (CD23) is expressed on additional cells, including B lymphocytes, where it is thought to play a role in IgE-mediated antigen presentation and the feedback regulation of IgE antibody production.

The IgE-Fc region contains three domains (Cε2–4). All three domains affect IgE receptor binding, yet the Cε3–4 fragment independently binds FcεRI and CD23 and contains the residues involved in IgE receptor interactions (Fig. 1a). The homodimeric IgE-Fc binds FcεRIα asymmetrically, forming two non-equivalent contacts with FcεRIα at the top of each Cε3 domain termed site 1 and site 2 (Fig. 1b) (ref. 5). Conformational rearrangements between open and closed states within the Cε3–4 fragment, stabilized by FcεRIα and CD23 binding, respectively, allow FcεRI and CD23 to function as reciprocal allosteric inhibitors (Fig. 1b) (refs 14,15). In contrast, Cε2 domains do not make extensive contact with IgE receptors, but form intramolecular contacts within IgE, stabilizing a ‘bent,’ asymmetric conformation of the full-length molecule (Fig. 1c). The primary role of the Cε2 domain is to contribute to the slow dissociation of IgE from FcεRIα (ref. 13).

IgE has been a target for therapeutic development because of its central role in the allergic response. The anti-IgE monoclonal antibody omalizumab is currently indicated for the treatment of moderate to severe persistent asthma and chronic idiopathic urticaria. Omalizumab has demonstrated robust clinical efficacy, and has promise for a wide range of other allergic conditions, including oral food allergen desensitization regimens. Omalizumab acts primarily by neutralizing free serum IgE. Thereby, it also reduces surface levels of IgE on FcεRI-expressing cells, including mast cells and basophils. As IgE surface levels decline on these allergic effector cells, they lose the ability to bind allergen and to undergo IgE-dependent activation.

Omalizumab received FDA approval over a decade ago; yet, no structure of the omalizumab:IgE complex has been determined. To understand the structural basis of omalizumab:IgE interactions and its ability to inhibit both FcεRI and CD23 binding, we determined the structure of the omalizumab Fab bound to a disulfide bond mutant of the IgE-Fc Cε3–Cε4 fragment (IgE-G335C-Fcε3–4) to 2.5 Å (Table 1). Omalizumab binds to the IgE Cε3 domains outside of the FcεRI-binding site, similar to the anti-IgE Designated Anykyrin Repeat Protein (DARPin) E2_79, in good agreement with prior mapping studies of the epitope. The complex structure clarifies how omalizumab blocks IgE interactions with both the high- and low-affinity receptors. Despite the similarity in omalizumab and E2_79-binding sites on IgE, E2_79 is a disruptive inhibitor that can accelerate the dissociation of IgE:FcεRI complexes, while omalizumab has only poor (~1,000-fold weaker) disruptive activity. Comparison of the omalizumab and E2_79 IgE complexes provides insights into the mechanism of disruptive inhibition, which could help in the development of anti-IgE antibodies with improved disruptive capabilities.

The omalizumab structure also facilitated the design of an IgE-Fcε3–4 mutant (IgE-R419N-Fc3–4) that is resistant to omalizumab neutralization but is able to bind CD23 and FcεRI. Significant experimental evidence has accumulated suggesting that IgE-dependent homeostatic regulatory pathways respond to the loss of receptor-bound IgE induced by omalizumab treatment, and could offset or constrain the therapeutic benefit of the anti-IgE treatment. We demonstrate that the IgE-R419N-Fc3–4 mutant, in combination with omalizumab, can effectively exchange cell-bound IgE with IgE-R419N-Fc3–4 and that this dual inhibitor treatment is more potent at blocking basophil activation than either inhibitor alone. This approach of simultaneously depleting antigen-specific IgE, while engaging FcεRI and CD23 receptors with an IgE variant, can be used to further probe the role of IgE-dependent regulatory pathways during anti-IgE treatment and may provide a route to enhance current anti-IgE therapies.

Results

Structure of the IgE–omalizumab complex. We previously described an IgE-Fcε3–4 mutant (IgE-G335C-Fcε3–4), which contains an engineered disulfide bond at position 335 that traps the IgE-Fcε3–4 domain in a closed conformation with reduced conformational flexibility (Fig. 1b). This variant retains high-affinity binding to omalizumab, but not FcεRIα (Supplementary Figs 1 and 2). Employing this restrained IgE-Fcε3–4 variant, we crystallized the IgE-G335C-Fcε3–4:omalizumab–Fab complex (subsequently referred to as the IgE:omalizumab complex). The purified complex (Supplementary Fig. 3a,b) crystallized in the P21 space group, diffracted X-rays to 2.5 Å (Table 1), and the structure was solved by molecular replacement using the existing model.

Figure 1 | Organization and conformational rearrangements of the IgE-Fc. (a) IgE and the relative locations of the FcεRI-α (purple) and CD23 (orange)-binding sites. (b) A representation of open and closed conformations of the IgE-Fcε3–4 domains (including the IgE-G335C-Fcε3–4 mutant locked in a closed conformation), and a representation of the reciprocal allosteric inhibition by FcεRIα (purple) and CD23 (orange). (c) A schematic of the bent conformation of IgE, and the relative position of the Cε2 domains.
IgE–G335C–Fc3–4 (ref. 33) and omalizumab–Fab structures. The asymmetric unit contains two copies of IgE–G335C–Fc3–4, and four copies of the omalizumab–Fab, providing four copies of the IgE:omalizumab interface related by non-crystallographic symmetry (NCS). Side-chain electron density was well resolved throughout the IgE:omalizumab interface (Supplementary Fig. 3c).

Analysis of the structure revealed that the omalizumab–Fab approaches perpendicularly to the IgE Cε3 domain, in contrast to recently proposed models, and contacts symmetric binding sites on the face of the two Cε3 domains of the IgE dimer (Fig. 2a–c). These contacts are predominantly formed between the omalizumab–Fab and Cε3 β-sheet residues below the FcRRIz-binding loops (FG, BC and DE; Fig. 2d). Structural alignment of the IgE:FcRRIz complex with the IgE:omalizumab complex shows that the binding loops are only slightly perturbed within the IgE:omalizumab complex at receptor site 2 (Fig. 2d); thus, omalizumab does not appear to inhibit IgE:FcRRIz interactions by distorting the FcRRIz-binding site. Instead, the omalizumab–Fab is positioned between the binding sites of both FcRRI and CD23, blocking interactions with both receptors, with the heavy chain proximal to the CD23 site, and the light chain proximal to the FcRRIz-binding sites (Fig. 2d). Of note, both the position of the omalizumab epitope on the face of Cε3, and the perpendicular binding orientation of the omalizumab Fab, suggest that omalizumab could approach and target a preformed IgE–FcRRI complex.

Impact of IgE-Fc conformation on omalizumab binding. We previously demonstrated that omalizumab can bind preformed IgE-Fc3-4:FcRRIz complexes, but not full-length IgE:FcRRIz complexes. Therefore, we hypothesized that the Ca2 domains of full-length IgE in the IgE:FcRRIz complex obscure an omalizumab-binding site that is exposed in the IgE-Fc3-4:FcRRIz complex. As predicted, alignment of the structures of IgE:omalizumab and IgE-Fc3-4:FcRRIz complexes demonstrates that the Ca2 domains overlap extensively with an otherwise exposed omalizumab-binding epitope in the IgE-Fc3-4:FcRRIz structure (Fig. 2e). Therefore, omalizumab’s specificity for free IgE is not solely determined by FcRRIz competition, but also by IgE-conformation-dependent masking of its own second omalizumab epitope. These observations suggest that fragmented IgE molecules lacking Cε2 could be aggregated by omalizumab, leading to basophil activation (Supplementary Fig. 4); however, we have not observed this in human basophils or mast cells.

Given that the crystal structure lacks the Cε2 domain, it cannot account for possible contributions of the Cε2 to omalizumab:IgE interactions. Therefore, we also compared the binding kinetics of full-length IgE (clone Sus11) to that of the IgE-Fc3-4 fragments. We hypothesized that the kₐ of full-length IgE might be slower than that of IgE-Fc3-4 because the Cε2 domains obscure one of the two symmetric omalizumab epitopes (Fig. 1), and, as expected, the kₐ of full-length IgE was 15–30-fold lower compared with the IgE-Fc3-4 fragments tested (Supplementary Fig. 1). Surprisingly, the kₐ of the full-length IgE was also 4.5–10.9-fold slower than any of the three IgE-Fc3-4 fragments tested (Supplementary Fig. 1). This result is due to differences in the equilibrium constant Kₐ in the IgE-Fc3-4 fragments.

The IgE Cε3 domains also show significant conformational flexibility, adopting closed and open states relative to the Cε4 domains that are associated with CD23 and FcRRI binding, respectively. The potential impact of these conformational changes on omalizumab binding has not been fully assessed. The localization of the omalizumab epitope on the face of the Cε3 domain suggested that omalizumab would interact equally well with both open and closed forms of the IgE-Fc. To examine this possibility, we compared the binding kinetics of omalizumab with wild-type IgE-Fc3-4, the IgE-G335C-Fc3-4 mutant (locked in the closed conformational state) and with IgE-Fc3-4 bound to FcRRIz (stabilized in the open state by receptor binding). IgE-G335C-Fc3-4 exhibited similar kinetics in omalizumab-binding studies as wild-type IgE-Fc3-4 (Supplementary Fig. 1) but was unable to bind FcRRIz (Supplementary Fig. 2). These data suggest that omalizumab can bind closed conformations of IgE efficiently, and indicate that the crystal structure reflects the normal binding mode of omalizumab for IgE-Fc3-4.

No mutations have been identified that stabilize the open IgE-Fc3-4 conformational state, making studies of the omalizumab interaction with this state more challenging. However, omalizumab binds to IgE-Fc3-4:FcRRIz complexes, and our structural analysis demonstrates that one of the two Cε3 domain epitopes is fully accessible to omalizumab. Therefore, to examine the potential impact of the open Cε3 domain conformation on omalizumab binding, we measured the kinetics of omalizumab binding to preformed IgE-Fc3-4:FcRRIz complexes. This analysis revealed an association rate constant (kₐ) for omalizumab with IgE-Fc3-4 bound to FcRRIz complexes that was closer to full-length IgE alone and slower than unbound IgE-Fc3-4. The similarity in association rates between full-length IgE and IgE-Fc3-4:FcRRIz complexes may be in part because of the fact that each binding partner contains a single exposed Cε3 domain (Supplementary Fig. 5). The dissociation rate constant (kₐ) for the omalizumab/IgE-Fc3-4:FcRRIz complexes was also similar to that of the measured rates for IgE:FcRRIz or omalizumab/IgE complexes (Supplementary Figs 1 and 2), consistent with the dissociation of either of these two interfaces during measurement. Together, these kinetic data demonstrate that the IgE-Fc Cε3 conformations have little or no impact on omalizumab binding.
perturbations in the Fc sites within the IgE–C domains. (Fig. 3d,e) The side view of the biologic unit of the IgE:omalizumab complex shows the omalizumab–Fab approaching perpendicularly relative to the Cε3–Cε4 domains. (c) The top view of the complex reveals the two nonoverlapping and symmetric omalizumab epitopes on each Cε3 domain within the IgE. (d) Comparison of IgE:omalizumab, FcεRIα (1F6A) and CD23 (4E2M) complexes demonstrates that omalizumab binds between CD23 and FcεRIα-binding sites within the IgE-Cε3 domain. Alignment of the IgE:omalizumab complex with the Cε3 domain of the IgE:FcεRIα complex, in magenta, reveals no major perturbations in the FcεRIα-binding loops. (e) Omalizumab and Cε2 directly compete for IgE-binding sites of the surface of IgE.

and that, in free IgE, the Cε2 domain may alter the kinetics of omalizumab binding with a small effect on the affinity of the interaction. These data support the structural observation that omalizumab:IgE interactions are primarily mediated by a stable epitope contained in the Cε3 domain. These kinetic data also highlight the critical role of the Cε2 domains in the intact receptor-bound IgE, which are required to mask an omalizumab epitope that is not directly blocked by the FcεRI itself.

The omalizumab epitope. To establish which residues fall within the omalizumab epitope on IgE, we analysed the interfaces of the omalizumab:IgE complex with PISA. All NCS copies shared the majority of contacts, which extend along the length of the Cε3 domain, involve 23 IgE residues and bury ~725 Å² of surface area on IgE (Fig. 3a). Previously identified IgE mutants that inhibit omalizumab binding, studied in an intact IgE heavy chain, correspond well with the binding interface observed in the crystal structure (Fig. 3b) (ref. 24). After correcting for different numbering schemes and IgE sequences from prior studies (Supplementary Fig. 6), all residues implicated in omalizumab: IgE binding are within the predicted omalizumab:IgE interface, and many participate in hydrogen bonds (R376, S378, K380, Q417) or salt bridges (R419) predicted by the crystal structure (Fig. 3c–e). Notably, IgE E414, a residue implicated in omalizumab-binding studies with the mutants E414R/Q, appears to form an intrachain salt bridge with IgE R376 (Fig. 3d) and may be essential for stabilizing the conformation of the adjacent omalizumab-binding residues (Fig. 3d,e).

The omalizumab complementarity-determining region (CDR) loops, with the exception of the light chain CDR3 loop, contact IgE. CDR residues previously shown to be required for omalizumab binding either contact IgE (light chain D32 in CDR1 (Fig. 3c) and heavy chain H101 in CDR3 (Fig. 3e)) or form interactions with neighbouring CDR loops (heavy chain CDR3 H105 and H107) (ref. 24). The complex contains five hydrogen bonds distributed throughout the omalizumab:IgE interface and two salt bridges between light chain residues D32 and D34 and IgE R419 (Fig. 3c–e). The heavy chain CDR3, which shows the most extensive conformational change from the unbound omalizumab:Fab structure (PDB ID: 4X7S), also contains three aromatic side chains that contact IgE (Y102, H101, F103; Fig. 3e). Outside of the omalizumab heavy chain CDR3, four additional aromatic side chains contact IgE: Y33 in the heavy chain CDR1, Y36 in the light chain CDR1 and Y53 and Y57 in the light chain CDR1. Therefore, it appears that a network of hydrogen bonds, salt bridges and extensive hydrophobic interactions facilitate omalizumab:IgE interactions.

The IgE residues interacting with omalizumab CDRs are largely distinct from those that engage FcεRIα (ref. 24). IgE residues P426 and R427 are the only minor overlapping portions of the omalizumab:IgE-Fcε3 and FcεRIα:IgE-Fcε3 interfaces as calculated with the PISA analysis (Fig. 3a). Each residue is unique to site 2 of the FcεRIα:IgE complex. The residues are adjacent to the omalizumab light chain framework region (Fig. 3a and Supplementary Fig. 7) and are peripheral to the omalizumab:IgE interface. Only one NCS-related IgE chain has well-resolved electron density for R427, while the remaining copies do not (Supplementary Fig. 7). Within this chain neither R427 nor P426 makes contacts (<4 Å) directly with omalizumab; however, R427 indirectly interacts with the light chain framework through a
Although omalizumab may directly compete with FcεRI for receptor-binding residues on IgE, steric clashes caused by physical overlap of omalizumab and IgE could affect receptor binding. Omalizumab also shows minimal inhibition of CD23 binding (Fig. 4b,c). The degree of steric overlap of omalizumab with CD23 is significantly greater than that observed for FcεRIβ. Both substantial steric overlap between omalizumab and CD23, and direct competition for IgE-binding residues by the omalizumab heavy chain, contribute to omalizumab inhibition of CD23 binding (Fig. 4b,c). The degree of steric overlap of omalizumab with CD23 is significantly greater than that observed for FcεRIβ (Fig. 4b). Binding-site comparisons also demonstrate a more extensive overlap between IgE residues that engage omalizumab and CD23 in their respective complexes as compared with FcεRIβ (Fig. 4c).

Figure 3 | The omalizumab epitope. (a) A top down overview of the omalizumab:IgE complex, with interface residues coloured green and residues shared between omalizumab:IgE and IgE:FcεRIβ complexes labelled. (b) Position of previously published IgE heavy chain mutants and a new IgE-FcεRIβ mutant (R419N) at the omalizumab interface in green. Mutant residues are colour-coded by their relative binding to omalizumab (magenta 0–14%, blue 15–44% and orange 44–75% of wild-type IgE). (c–e) Detailed view of the omalizumab:IgE interface, with distances (Å) between atoms predicted to participate in hydrogen bonds or salt bridges shown in black. (c) A hydrogen bond between IgE Q417 and omalizumab light chain Y53, and a salt bridge between IgE R419 and light chain D34 and D32. (d) A hydrogen bond between IgE K380 and omalizumab heavy chain S31, and an intrachain salt bridge between IgE E414 and IgE R376, two residues implicated in omalizumab:IgE binding studies. (e) Hydrogen bonds observed between IgE residues R376, A377, S378 and omalizumab heavy chain residues H101 and Y33.

The structural basis of FcεRI and CD23 competition. Omalizumab inhibition of FcεRIβ and CD23 binding could arise from contributions of multiple structural mechanisms, including direct competition for receptor-binding residues on IgE, steric clashes caused by physical overlap of omalizumab and IgE receptors and potential omalizumab-induced conformational changes in IgE. The kinetic and structural data suggest that omalizumab does not induce conformational changes in FcεRIβ-binding loops or in the relative positions of the Cε3 domains that could affect receptor binding. Omalizumab also shows minimal overlap with FcεRIβ-binding residues; however, physical overlap between the bound omalizumab Fab and FcεRIβ could be substantial and critical to omalizumab activity.

To gain quantitative insight into the contribution of inhibitor overlap in blocking IgE interactions with FcεRIβ and CD23, we calculated the theoretical volumes of atomic overlap between omalizumab and its two IgE receptors. First, we performed a structural alignment of the Cε3 domain of the IgE:omalizumab complex with the Cε3 domain of the IgE:FcεRIβ complex at sites 1 and 2 (Fig. 4a). This alignment strategy accounts for the variability of open and closed IgE conformations observed across IgE crystal structures.24,38 We then calculated the volume of atomic overlap between the superimposed omalizumab and FcεRIβ proteins. This analysis revealed that, for the omalizumab-binding site proximal to FcεRIβ binding site 2, there are significant steric clashes between the antibody light chain and both domains of the FcεRIβ receptor (Fig. 4a), while no clashes exist at site 1. These structural data indicate that omalizumab’s mechanism of FcεRIβ inhibition involves substantial steric conflict with the receptor at site 2, while direct competition for FcεRIβ-binding residues is limited.

Omalizumab has also been shown to inhibit the binding of CD23 (ref. 39). Both substantial steric overlap between omalizumab and CD23, and direct competition for IgE-binding residues by the omalizumab heavy chain, contribute to omalizumab inhibition of CD23 binding (Fig. 4b,c). The degree of steric overlap of omalizumab with CD23 is significantly greater than that observed for FcεRIβ (Fig. 4b). Binding-site comparisons also demonstrate a more extensive overlap between IgE residues that engage omalizumab and CD23 in their respective complexes as compared with FcεRIβ (Fig. 4c).
Steric overlap and inhibitor-induced FcεRIα complex dissociation.

We recently described a class of IgE inhibitors derived from Designed Ankyrin Repeat Protein (DARPin) libraries, capable of disrupting IgE:FcεRIα complexes\(^{23,25}\). These agents target preformed IgE:FcεRIα complexes found on mast cells and basophils and accelerate the dissociation rate constant to release free IgE. The activated release of IgE on the surface of effector cells might prove beneficial in treating acute allergic reactions and enhance the clearance of allergen-specific IgE during anti-IgE therapy by targeting both cellular and serum pools of IgE simultaneously. We have demonstrated that a bivalent DARPin (bi53_79) containing a non-competitive IgE-binding domain and a disruptive competitor domain dissociates complexes with greater efficiency \textit{in vitro} and shows greater potency than omalizumab in blocking passive cutaneous anaphylaxis in mice bearing the human FcεRI receptor\(^{25}\). To our surprise, we also observed that omalizumab is not strictly a competitive inhibitor of IgE:FcεRIα interactions, but at higher concentrations it is also capable of targeting and disrupting IgE:FcεRIα complexes\(^{23,25}\).

We have published the crystal structure of the DARPin-based inhibitor E2_79 (ref. 23), which is able to accelerate the dissociation of FcεRIα complexes at concentrations \(\sim 3,000 \times\) above the E2_79:IgE \(K_D\) (ref. 23). In contrast, omalizumab shows an ability to disrupt preformed FcεRIα complexes at concentrations that are much higher (\(\sim 1,000,000\)-fold greater) than the omalizumab:IgE \(K_D\) (ref. 25), indicating that it is much less efficient at the process of binding to and dissociating these preformed complexes. We hypothesized that this difference in disruptive capability was related to the binding-site locations for E2_79 and omalizumab on IgE and the level of atomic overlap between each inhibitor and receptor. We therefore compared the structure of both the E2_79-IgE-G335C-FcεRIα complex (E2_79-IgE) and the omalizumab:IgE complex.

The structure of the E2_79-IgE complex demonstrated that the E2_79-binding sites do not overlap with FcεRIα-binding residues, while omalizumab exhibits only minor peripheral interactions with two FcεRIα-binding residues\(^{23}\). Instead, similar to omalizumab, E2_79 exhibited steric conflicts with FcεRIα in aligned structures of the complexes. Given that both agents can disrupt preformed IgE:FcεRIα complexes\(^{23}\), we sought to quantitatively compare their relevant steric clashes with FcεRIα when bound to IgE, by computing the predicted volume of atom–atom overlap of each inhibitor with FcεRIα in aligned complex structures. This analysis reveals that omalizumab has roughly three times the volume of atomic overlap with FcεRIα compared with E2_79 (omalizumab and FcεRIα = 1,183 Å\(^3\) versus E2_79 and FcεRIα = 401 Å\(^3\)). The omalizumab steric conflicts extend along the length of the omalizumab light chain and FcεRIα N-terminal domain, while the E2_79 steric conflicts are more localized near the IgE:FcεRIα interface (Fig. 4a and 4d) (ref. 40). Since the E2_79 and omalizumab-binding sites are substantially overlapping on the IgE-FcεRIα complex (Supplementary Fig. 8), this large difference in steric overlap with FcεRIα stands out as a prominent structural feature that correlates with the relative disruptive activities of these inhibitors. Conformational dynamics in the IgE:FcεRIα complex may transiently allow E2_79 association and subsequent acceleration of FcεRIα dissociation\(^{23}\). Given the significantly larger region of steric conflicts observed between omalizumab and FcεRIα, conformational states of the IgE:FcεRIα that could accommodate omalizumab association may simply be
A single IgE mutation prevents omalizumab binding. To further validate observations from the crystal structure, we produced an additional IgE-Fc3–4 mutant. IgE residue R419 lies at the interface of the IgE:omalizumab complex, forming contacts with both light and heavy chain CDR loops (Fig. 3c) and participating in salt bridges. Mutation of R419 to an asparagine (R419N) introduces the glycosylation consensus sequence—asparagine valine threonine (NVT) (Fig. 5a). We hypothesized that mutating this residue we would abolish omalizumab binding by introducing a glycosylation site at the core of the omalizumab epitope.

The R419N mutation induced a shift in the mass of recombinant IgE-Fc3–4 as assessed by SDS–PAGE and gel filtration, consistent with the introduction of an additional N-linked glycan (Fig. 5a,b). The IgE-Fc3–4 contains two N-linked glycosylation sites, N371 and N394 (refs 41,42). We have found in recombinant preparations of IgE-Fc3–4 that glycosylation at N371 is heterogeneous and leads to a minor band in purified material (Fig. 5b). Both major and minor species of IgE-R419N-Fc3–4 remain in similar proportions to wild-type IgE-Fc3–4 species, with similar mobility shifts in SDS–PAGE. Furthermore, the shift in apparent mass for IgE-R419N-Fc3–4 relative to wild-type IgE-Fc3–4 was lost on digestion with PNGaseF, confirming that it is caused by N-linked glycosylation (Fig. 5b). This additional glycosylation in the middle of the omalizumab epitope completely abolishes omalizumab binding, but only slightly perturbs IgE-R419N-Fc3–4 binding to FcεRIα as assessed by surface plasmon resonance (SPR; Fig. 5c,d and summary data Supplementary Figs 1 and 2). Taken together, these data demonstrate that the R419N mutation introduces a novel glycosylation site to yield an omalizumab-resistant IgE-Fc3–4 variant.

Exchange of IgE on human basophils. The paradigm of using anti-IgE treatment to deplete free IgE (both allergic and non-allergic species) has proven successful for controlling allergic diseases. During omalizumab therapy, omalizumab neutralizes free serum IgE and slowly decreases surface levels of IgE on allergic effector cells. Therefore, it is impossible to simultaneously replace depleted allergen-reactive species with benign IgE species because of the requirement for continued excess omalizumab to be present during treatment. Since IgE-dependent homeostatic regulatory pathways could potentially counteract anti-IgE therapies, we sought to explore the possibility of replacing rather than removing patient IgE. We hypothesized that omalizumab-resistant IgE variants or fragments could be used in combination with omalizumab to effectively exchange the native IgE on human cells bearing FcεRI or CD23.

Over the course of omalizumab treatment, free IgE levels and IgE surface levels on basophils decline relatively rapidly within days43, while mast cell IgE levels persist for significantly longer44. The rapid decline of basophil-associated IgE may in part be driven kinetically by basophil turnover in vivo45. However, within the experimental timeframe for our ex vivo experiments with human whole blood (24–48 h), we did not observe significant loss of cell surface IgE at doses corresponding to the mean omalizumab serum concentrations from clinical trials46. Therefore, we employed supraphysiologic doses of omalizumab (25 μM) to enhance the removal of IgE as described previously25. These doses were used here to accelerate the loss of cell-bound IgE to facilitate these exchange experiments. Nonetheless, lower
therapeutic doses of omalizumab are sufficient to capture free IgE and reduce cell surface levels of IgE over time, which is the basis of omalizumab’s therapeutic effect.

To track the addition, removal and exchange of IgE species, we employed biotinylated IgE-Fc3–4 or omalizumab-resistant IgE-R419N-Fc3–4, and the JW8 human/mouse chimeric IgE (composed of a human IgE heavy chain and a mouse-λ-light chain). The JW8 mouse-λ-light chain allowed us to track IgE reloading on stripped basophils in parallel with the biotinylated IgE-Fc3–4 proteins. We ensured that all antibody reagents used in staining carried the mouse-κ-light chain, or were rat antibodies, to avoid nonspecific binding from the anti-mouse-λ-light-chain antibody used to track JW8-IgE.

We isolated blood from three donors, and depleted surface IgE on basophils by treating each sample with the disruptive inhibitor E2_79 (Fig. 6a, gating scheme Supplementary Fig. 9). We then reloaded the cells with JW8-IgE (Fig. 6a), while also verifying that stripped cells could be reloaded with biotinylated IgE-Fc3–4 or IgE-R419N-Fc3–4 species (Fig. 6a). Therefore, we could remove native IgE species, reload cells with homogeneous traceable IgE and subsequently track the removal or exchange of JW8-IgE (Fig. 6b,c). The λ-light-chain-specific staining of JW8 and biotin-specific staining of the IgE-Fc3–4 variants distinguished human basophils that had no JW8-IgE or biotinylated-IgE-Fc3–4, a mix of both species, or a single IgE species (Fig. 6b,c).

Overnight omalizumab treatment of cells that had been homogenously reloaded with JW8-IgE completely removed the JW8-IgE from the cell surface, as shown by an overlay of the pre- and post-treatment flow cytometry profiles (arrow, Fig. 6d). Co-administration of IgE-Fc3–4 and omalizumab also showed complete depletion of JW8-IgE species but no exchange for IgE-Fc3–4 at 1 µg ml$^{-1}$ IgE doses (Fig. 6d). In contrast, co-administration of omalizumab-resistant IgE-R419N-Fc3–4 with omalizumab depleted JW8-IgE surface levels, and facilitated IgE-R419N-Fc3–4 reloading to levels observed in IgE-stripped basophils treated with IgE-R419N-Fc3–4 alone (Fig. 6d). Therefore, co-administration of omalizumab and IgE-R419N-Fc3–4 effectively exchanges the receptor-bound IgE on human basophils for IgE-R419N-Fc3–4 ex vivo. Even when wild-type IgE-Fc3–4 doses far beyond physiologic IgE levels were employed

---

**Figure 6 | Exchange of IgE on human basophils.** (a) Left panel: 2-h treatment with 25 µM E2_79 removes surface IgE from primary human basophils, but does not alter surface FcγRII levels within 24 h. Middle panel: E2_79-treated basophils can be reloaded with JW8-IgE and tracked by JW8’s mouse-λ-light chain (λ-LC). Right panel: biotinylated WT and IgE-R419N-Fc3–4 variants bind E2_79-treated basophils. (b) Experimental design for the IgE exchange. In brief, IgE is removed from primary basophils using E2_79. JW8-IgE is then reloaded on basophils to generate a traceable starting IgE population. (c) Experimental validation shows distinct populations of basophils with JW8-IgE (Q1), JW8-IgE and biotinylated IgE-Fc3–4 (Q2), biotinylated IgE-Fc3–4 alone (Q4) and E2_79-treated cells without labelled IgE (Q3; displaying merged dot plots from each sample). (d) All panels show starting JW8-reloaded population in Q1 before treatment, and cells after treatment. Left panel: overnight treatment with high-concentration omalizumab (25 µM) is sufficient to remove the majority of JW8-IgE. Middle panel: overnight treatment of cells with omalizumab (25 µM) and IgE-Fc3–4 (1 µg ml$^{-1}$ or ~18 nM) results in depletion of JW8-IgE, but no exchange for IgE-Fc3–4. Right panel: overnight treatment of cells with omalizumab (25 µM) and IgE-R419N-Fc3–4 (1 µg ml$^{-1}$ or ~18 nM) results in depletion of JW8-IgE, and IgE exchange to IgE-R419N-Fc3–4. (Representative dot plots shown. N = 3 at 10 µg ml$^{-1}$ IgE-Fc doses and controls, and N = 3 at 1 µg ml$^{-1}$ IgE-Fc doses).
basophils showed reduced activation, which likely reflects the spontaneous loss of IgE. Furthermore, in combination with omalizumab, 1 nM IgE-R419N-Fc3–4 almost completely inhibited basophil activation (Fig. 7b). The additive effect of omalizumab (500 nM) and IgE-R419N-Fc3–4 (1 nM) should be minor if each agent acted only as a competitive inhibitor for JW8-IgE:FcRRIa interactions, suggesting that these agents can act synergistically to block basophil activation.

**Discussion**

Anti-IgE therapy remains an important tool for the management of allergic disorders, and novel second-generation anti-IgE therapies will soon join omalizumab. Yet, the aetiology of allergic disorders is complex and optimal therapeutic responses will likely come from treatment regimens that target and modulate multiple immunological processes.

Here we have clarified the structural basis for omalizumab-mediated inhibition of IgE binding to both FcεRI and CD23. This analysis revealed similarities between the disruptive inhibitor E2_79 and omalizumab, and provides a mechanistic framework to develop antibody-based therapies that can accelerate the dissociation of IgE:FcεRIa complexes. Such agents could rapidly disarm basophils and mast cells, allowing them to achieve a therapeutic effect faster.

We have also demonstrated that mutant IgE fragments, in conjunction with omalizumab treatment, can exchange native IgE on human cells for IgE fragments, maintaining the occupancy of both high- and low-affinity IgE receptors. We pursued this approach, given the experimental evidence that basophils increase in sensitivity on a per IgE basis during omalizumab treatment28,30, and that IgE production can be regulated by IgE:CD23 signalling8,11,12,31,32. These observations raise significant questions about the impact of therapeutic IgE depletion, and suggest that homeostatic responses to the loss of IgE could offset or constrain the therapeutic benefit of anti-IgE treatment. Our experimental observations provide a system to test some of these regulatory pathways and could potentially be used as an adjunct therapy with omalizumab. To this end, we have also demonstrated that IgE-R419N-Fc3–4 can act synergistically with omalizumab ex vivo at very low doses to inhibit basophil activation. This finding suggests that simultaneously targeting FcεRI and IgE with competitive inhibitors could enhance therapeutic responses. Prior studies have demonstrated that

**Figure 7 | IgE-R419N-Fc3–4 and omalizumab act synergistically.** Human basophils from three healthy volunteers were isolated, stripped of native IgE by bi53_79 DARPin treatment and reloaded with NP-reactive JW8-IgE. These NP-reactive basophils were then cultured with or without omalizumab and IgE-R419N-Fc3–4 as indicated for 3 (a) or 6 (b) days before antigen challenge. Basophil activation was assessed by the per cent of CD63-positive cells. There was a statistically significant difference between groups as determined by a repeated-measures analysis of variance ($F = 7.4$, $P = 0.0004$ Day 3 and $F = 19.3$, $P = 0.0001$ Day 6), and a Tukey post hoc test was used to determine the significance of differences between groups. On day 6, the untreated basophils showed reduced activation, which likely reflects the spontaneous loss of IgE.
non-activating ligands can antagonize FcεRI responses to activating ligands by sequestering receptor-proximal signalling components\textsuperscript{13}, and it is possible that IgE-R419N-FcεRI complexes could suppress activation through such mechanisms, in addition to competing for receptor occupancy. Sustained FcεRI receptor occupancy could also suppress homeostatic responses to the loss of IgE on omalizumab-treated basophils.

Finally, the dissociation of allergen-specific IgE on mast cells located in peripheral tissues is slow, and the effectiveness of anti-IgE within these compartments is poorly understood\textsuperscript{48}. Given that the FcεRI on mast cells has been shown to drive IgE tissue localization\textsuperscript{48,49}, co-administration of omalizumab and omalizumab-resistant IgE fragments that bind FcεRI may enhance the exchange of allergen-specific IgE in peripheral sites, and contribute to the therapeutic benefit of anti-IgE treatment.

Despite the potential utility of IgE exchange, and promising ex vivo results, the concept is far from clinical application. Unexpected antibody responses to the R419N IgE, although unlikely, could prevent the development of any universally benign IgE variant for exchange therapy, and could induce anaphylactic and in vivo responses to receptor-bound IgE fragments. Yet, our approach with IgE-R419N-FcεRI does have two distinct advantages in this regard. First, N-linked glycosylation events are effective at masking antibody epitopes, and could reduce the immunogenicity of IgE-R419N-FcεRI (ref. 49). Second, the new antigenic surface generated by truncating IgE to the Cε3-4 domains would be largely inaccessible once bound to FcεRI, preventing any antibody responses to this epitope from crosslinking receptor-bound IgE fragments. Given that anti-IgE and anti-FcεRI antibody responses are relatively common, and are not always pathological\textsuperscript{30}, it is possible that such an approach could be well tolerated.

**Methods**

**Preparation of omalizumab and recombinant proteins.** Fab fragments of Omalizumab (Numaris) were prepared by digestion over an immobilized ficin agarose resin (Pierce) in 10-mM citrate buffer with 25 mM cysteine and 5 mM EDTA at pH 6.0 for 5 h. The Fab fragments were purified in two steps with protein G (Pierce) and gel filtration to yield homogenous omalizumab-Fab. Protein G columns were washed with phosphate buffer over a pH gradient (8.0, 7.0, 6.0 and 5.0) and Fab was eluted with glycine buffer at pH 2.5. Insect-cell-derived IgE-FcεRI, IgE-G353C-FcεRI, and FcεRIz were expressed in High Five insect cells and purified using IMAC affinity chromatography and further purified using gel filtration on a Superdex 200 10/300 GL column (GE). All insect vectors have been previously published: IgE-FcεRI (ref. 33), IgE-G353C-FcεRI (ref. 33) and FcεRIz\textsuperscript{31}.

Mammalian-derived IgE-FcεRI and the R419N mutant, used in all cell-based assays, were cloned into the pYD7 vector (National Research Council (NRC), Canada) with a vascular endothelial growth factor (VEGF) signal sequence from the pTV/THV8 vector (NRC). Constructs were transfected using 25-kDa linear polyethylenimine (Polysciences), and transiently expressed in suspension HEK-293 cells, as specified in the figure legends with omalizumab, IgE-Fc variants or vehicle controls. The following day cells were washed three times with BF buffer at 4°C and stained for flow analysis.

**Biotinylation of proteins.** IgE-FcεRI, or R419N IgE-FcεRI, was biotinylated using EZ-Link Sulfo-NHS-LC-biotin (Pierce), with a 30-fold molar excess of sulfo-NHS-LC-biotin for 30 min at room temperature. The reaction was stopped using 1.0 M Tris pH 7.4, and proteins were dialysed overnight into PBS pH 7.4, and sterile-filtered with 0.22-μm filter.

**Basophil IgE exchange experiments.** Blood was drawn from two healthy volunteers and a third volunteer with a history of food allergy ranging in age from 21 to 37 (the protocol for this study was approved by the Institutional Review Board of Stanford University, and all informed consent was obtained from all subjects). Blood was collected in heparin vacutainer tubes (BD), and washed in 10 blood volumes of BF buffer (RPMI-1640 (Life Technologies) supplemented with 10% fetal calf serum (FCS; Gibco) and 1% penicillin/streptomycin (Gibco)). Washed blood cells were then suspended in their original blood volume in BF buffer and treated with or without E2\textsubscript{79} at 25 μM for 2 h at 37°C to remove surface IgE. Stripped cells were then reloaded with IgE-JW8 at 120–300 ng ml\textsuperscript{-1} as estimated from supplier’s supplied concentration range (AbD Serotec) or were left untreated. These cells were then treated overnight at 37°C, as specified in the figure legends with omalizumab, IgE-Fc variants or vehicle controls. The following day cells were washed three times with BF buffer at 4°C and stained for flow analysis.

**Flow cytometry for basophil IgE exchange.** After washing, treated cells and controls were incubated with human Fc-block (BD), and stained with the following antibodies as described in figure legends (at 1:100 dilution unless stated): IgE-FITC (e Biosciences clone: IgE21), FcεRI-APC (e Biosciences clone AER-37: at 1:50 dilution), anti-biotin Alexa 488 (e Biosciences clone: BK-1/39), anti-mouse-lambda-light-chain PE (BioLegend clone: RML-42), CD123 PE-Cy5 (BD clone: 9F5 at 1:20 dilution), HLA-DR PE-Cy7 (BioLegend clone L243 at 1:80 dilution), CD203c BV421 (BioLegend clone: NP4D6 at 1:50 dilution), CD19-PE (BD clone: HB19 at 1:50), CD23-BV421 (BioLegend EBVCS-5 at 1:50 dilution) and Aqua Live Dead Stain (Aqua Biogen Inc, at 1:50 dilution). Cells were then loaded into Becton-Dickinson (BioLegend) for 5 min at room temperature, and washed with FACS buffer (PBS supplemented with 10% FCS). Data were collected on a DxP FASSCAN from Cytek Development in Fremont, CA (10 colours with three lasers—488, 639, 407) using FlowJo CE and analysed using FlowJo (version 10).

**SPR assays.** SPR measurements were conducted on a BIACore X100 device and evaluated with the Blaevaluation software (GE Healthcare, Fairfield, USA). For kinetic analysis of different IgE fragments on omalizumab and rhFcεRI, response units of omalizumab or rhFcεRI were immobilized in acetate buffer (pH 4.5 for omalizumab and pH 4.0 for rhFcεRI) on flow cell 2 of a 25 μL chip (GE Healthcare). Flow cell 1 was activated and deactivated without immobilization, according to the manufacturer’s protocol. The different IgE fragments (produced as described above) or full-length SJ11 IgE were diluted in HBS-EP + running buffer (GE Healthcare) and injected for 120 s at a constant flow rate of 10 μl min\textsuperscript{-1}. Dissociation was assessed for 240 s under constant buffer flow.
For each measurement, the chip surface was regenerated with 50 mM NaOH. Individual sensorgram curves were exported to Excel, and graphs were prepared with the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, USA). In all experiments, unspecific binding to flow cell 1 was subtracted from the signal on flow cell 2.

**Functional assay with primary human basophils.** Human primary basophils were isolated from whole blood of volunteers with approval from the local ethics committee (KEK Bern). Informed consent was obtained from all donors in accordance with the Helsinki Declaration. Human basophils were isolated from three different donors, with total IgE levels ranging from 35 to 78 kU l⁻¹, by using Percoll density centrifugation of dextran-sedimented supernatants with further purification with the Miltenyi basophil isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany), as previously described. Total IgE levels of the donors were determined using Immunocap (Phadia, Uppsala, Sweden). Purified primary human basophils were seeded at 0.5 × 10⁶ cells per well in a 96-well plate in 50 μl of RPMI containing 10% heat-inactivated FCS, 100 IU ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin (medium). Cells were kept in a cell incubator at 37 °C, 5% CO₂. For desensitization, cells were treated with 50 μM disruptive anti-IgE inhibitor bs53.79 for 8 h in the presence of 10 ng ml⁻¹ IL-3 and subsequently washed three times with 150 μl PBS to remove dissociated IgE and anti-IgE inhibitor from the supernatant. For resensitization, cells were incubated with 100 nM JWR-IgE (NBS-C BioScience, Vienna, Austria) for 2 h in the presence of 10 ng ml⁻¹ IL-3. Subsequently, cells were washed twice with 150 μl PBS and treated with omalizumab, IgE Fc–F(ab')₂, or a combination of these molecules for 3 or 6 days at indicated concentrations. For determination of FcεRI activation, cells were stimulated with 1–1,000 ng ml⁻¹ IL-3 for 3 or 6 days at the indicated concentrations. For determination of baseline activation, cells were stimulated with 1–1,000 ng ml⁻¹ NIP(7)BSA (BioSearch Technologies, Petaluma, USA) in the presence of 10 ng ml⁻¹ IL-3 for 30 min at 37 °C, 5% CO₂. Subsequently, cells were stained with 10 μl anti-CD36 FITC anti-CCR3-PE staining mix (FK-CCR Flow CAST Bühlmann Laboratories AG, Gladbach, Germany), as previously described. Total IgE levels of the donors were determined using Immunocap (Phadia, Uppsala, Sweden) in accordance with the Helsinki Declaration. Human basophils were isolated from blood samples of healthy donors with total IgE levels ranging from 35 to 78 kU l⁻¹.

Individual sensorgram curves were exported to Excel, and graphs were prepared with the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, USA). In all experiments, unspecific binding to flow cell 1 was subtracted from the signal on flow cell 2.

For each measurement, the chip surface was regenerated with 50 mM NaOH. Individual sensorgram curves were exported to Excel, and graphs were prepared with the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, USA). In all experiments, unspecific binding to flow cell 1 was subtracted from the signal on flow cell 2.

**Functional assay with primary human basophils.** Human primary basophils were isolated from whole blood of volunteers with approval from the local ethics committee (KEK Bern). Informed consent was obtained from all donors in accordance with the Helsinki Declaration. Human basophils were isolated from three different donors, with total IgE levels ranging from 35 to 78 kU l⁻¹, by using Percoll density centrifugation of dextran-sedimented supernatants with further purification with the Miltenyi basophil isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany), as previously described. Total IgE levels of the donors were determined using Immunocap (Phadia, Uppsala, Sweden). Purified primary human basophils were seeded at 0.5 × 10⁶ cells per well in a 96-well plate in 50 μl of RPMI containing 10% heat-inactivated FCS, 100 IU ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin (medium). Cells were kept in a cell incubator at 37 °C, 5% CO₂. For desensitization, cells were treated with 50 μM disruptive anti-IgE inhibitor bs53.79 for 8 h in the presence of 10 ng ml⁻¹ IL-3 and subsequently washed three times with 150 μl PBS to remove dissociated IgE and anti-IgE inhibitor from the supernatant. For resensitization, cells were incubated with 100 nM JWR-IgE (NBS-C BioScience, Vienna, Austria) for 2 h in the presence of 10 ng ml⁻¹ IL-3. Subsequently, cells were washed twice with 150 μl PBS and treated with omalizumab, IgE Fc–F(ab')₂, or a combination of these molecules for 3 or 6 days at the indicated concentrations. For determination of FcεRI activation, cells were stimulated with 1–1,000 ng ml⁻¹ NIP(7)BSA (BioSearch Technologies, Petaluma, USA) in the presence of 10 ng ml⁻¹ IL-3 for 30 min at 37 °C, 5% CO₂. Subsequently, cells were stained with 10 μl anti-CD36 FITC anti-CCR3-PE staining mix (FK-CCR Flow CAST Bühlmann Laboratories AG, Gladbach, Germany), as previously described. Total IgE levels of the donors were determined using Immunocap (Phadia, Uppsala, Sweden) in accordance with the Helsinki Declaration. Human basophils were isolated from blood samples of healthy donors with total IgE levels ranging from 35 to 78 kU l⁻¹.
Acknowledgements

We thank the members of the Jardetzky, Nadeau and Eggel laboratories. This research was supported in part by National Institute of Health Research Grant AI 38,972, Department of Defense grant PR130130 (to T.S.J.), NIH U19 AI104209 (to K.C.N.), by a grant from the Foundation Acteria (to A.E.) and a Swiss National Science Foundation Ambizione grant PZ00P3_148185 (to A.E.). L.F.P. is supported by an NIH training programme in Immunology (T32 AI007290). Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH.

Author contributions

L.F.P., S.T., D.B., K.S. and M.T.G. contributed to the execution of the experiments. All authors contributed to the experimental design, discussed results and worked together on the manuscript.

Additional information

Accession codes: The reflection data and coordinates for the omalizumab:IgE complex have been deposited in the RCSB with PDB ID code 5HYS.

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Pennington, L. F. et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat. Commun. 7:11610 doi: 10.1038/ncomms11610 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/